TY - JOUR
T1 - Effectiveness of third-class biologic treatment in crohn’s disease
T2 - A multi-center retrospective cohort study
AU - Albshesh, Ahmad
AU - Taylor, Joshua
AU - Savarino, Edoardo V.
AU - Truyens, Marie
AU - Armuzzi, Alessandro
AU - Ribaldone, Davide G.
AU - Shitrit, Ariella Bar Gil
AU - Fibelman, Morine
AU - Molander, Pauliina
AU - Liefferinckx, Claire
AU - Nancey, Stephane
AU - Korani, Mohamed
AU - Rutka, Mariann
AU - Acosta, Manuel Barreiro De
AU - Domislovic, Viktor
AU - Suris, Gerard
AU - Eriksson, Carl
AU - Alves, Catarina
AU - Mpitouli, Afroditi
AU - Di Jiang, Caroline
AU - Tepeš, Katja
AU - Coletta, Marina
AU - Foteinogiannopoulou, Kalliopi
AU - Gisbert, Javier P.
AU - Amir-Barak, Hadar
AU - Attauabi, Mohamed
AU - Seidelin, Jakob
AU - Afif, Waqqas
AU - Marinelli, Carla
AU - Lobaton, Triana
AU - Pugliese, Daniela
AU - Maharshak, Nitsan
AU - Cremer, Anneline
AU - Limdi, Jimmy K.
AU - Molnár, Tamás
AU - Otero-Alvarin, Borja
AU - Krznaric, Zeljko
AU - Magro, Fernando
AU - Karmiris, Konstantinos
AU - Raine, Tim
AU - Drobne, David
AU - Koutroubakis, Ioannis
AU - Chaparro, Maria
AU - Yanai, Henit
AU - Burisch, Johan
AU - Kopylov, Uri
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti-Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second-and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second-and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
AB - Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti-Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second-and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second-and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
KW - Anti-TNF failure
KW - Crohn’s disease
KW - Treatment failure
KW - Treatment response
KW - Ustekinumab
KW - Vedolizumab
UR - http://www.scopus.com/inward/record.url?scp=85114078800&partnerID=8YFLogxK
U2 - 10.3390/jcm10132914
DO - 10.3390/jcm10132914
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34209880
AN - SCOPUS:85114078800
SN - 2077-0383
VL - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 13
M1 - 2914
ER -